Abve Regimen

Key Takeaways

• ABVE stands for doxorubicin, bleomycin, vinblastine, and etoposide — four agents used in combination against Hodgkin lymphoma.
• The regimen is most commonly used in risk-adapted protocols for children and adolescents with Hodgkin lymphoma.
• Treatment cycles are typically administered every 21 days, with dosages adjusted based on body surface area and response.
• Common side effects include bone marrow suppression, nausea, fatigue, and risk of pulmonary toxicity from bleomycin.
• Response assessment after initial cycles guides whether therapy is escalated or de-escalated.

ABVE Regimen (Doxorubicin, Bleomycin, Vinblastine, Etoposide) in Hodgkin Lymphoma

The ABVE chemotherapy regimen for Hodgkin lymphoma combines four active agents: doxorubicin, bleomycin, vinblastine, and etoposide. Each drug targets cancer cell replication through a distinct mechanism. Doxorubicin intercalates DNA and inhibits topoisomerase II; bleomycin induces DNA strand breaks; vinblastine disrupts microtubule formation; and etoposide also inhibits topoisomerase II, reinforcing cytotoxic activity across the cell cycle. This multi-agent approach reduces the likelihood of drug resistance while allowing lower individual doses compared to single-agent therapy.

Hodgkin lymphoma accounts for roughly 15% of all childhood cancers, making effective and well-tolerated regimens a clinical priority (American Cancer Society). The ABVE protocol was developed within risk-adapted frameworks — most notably studied by the Children’s Oncology Group — to tailor treatment intensity to disease stage and early response. Patients classified as intermediate or high risk may receive ABVE alone or as part of a combined modality strategy that includes involved-field radiation therapy. Early response, typically assessed by imaging after two cycles, determines whether the regimen is continued, escalated, or reduced.

The rationale for combining these specific agents lies in their complementary mechanisms and non-overlapping toxicity profiles, which allow clinicians to maximize efficacy while managing cumulative harm. Response rates in clinical studies of pediatric Hodgkin lymphoma using ABVE-based protocols have been favorable, with event-free survival rates commonly reported above 85% in lower-risk cohorts.

ABVE Regimen Dosage, Administration, and Common Side Effects

The ABVE doxorubicin bleomycin vinblastine etoposide protocol is administered in 21-day cycles, with each agent delivered intravenously on designated days within the cycle. Dosages are calculated based on body surface area (mg/m²) and are individualized according to the patient’s age, weight, organ function, and overall treatment plan. Bleomycin is typically given on days 1 and 8, while doxorubicin, vinblastine, and etoposide are administered according to the specific cycle schedule outlined in the treating institution’s protocol.

Understanding the ABVE regimen side effects and dosage profile is essential for both patients and clinicians. The most clinically significant adverse effects include:

• Myelosuppression: Reduced production of blood cells, increasing the risk of infection, anemia, and bleeding.
• Pulmonary toxicity: Associated with bleomycin, which can cause lung inflammation or fibrosis, particularly with cumulative doses.
• Peripheral neuropathy: Linked to vinblastine, presenting as numbness or weakness in the extremities.
• Cardiotoxicity: A long-term concern with doxorubicin due to its cumulative effect on cardiac muscle.

Additional common side effects include nausea, vomiting, mucositis, alopecia, and fatigue. Supportive care — including antiemetics, growth factors such as granulocyte colony-stimulating factor (G-CSF), and infection prophylaxis — is routinely integrated to manage these effects and allow full-dose delivery. Long-term follow-up is strongly recommended given the risk of late effects, including secondary malignancies and cardiovascular complications, particularly in pediatric survivors.

Patients receiving this regimen should be monitored closely with regular blood counts, pulmonary function tests, and cardiac evaluations. Dose modifications may be required based on toxicity assessments, and all treatment decisions must be made by a qualified oncologist in accordance with the patient’s specific clinical situation.